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RESUMO
A terapêutica farmacológica consiste, frequentemente, num equilíbrio entre os efeitos benéficos e prejudiciais dos fármacos. As reações 
alérgicas a fármacos são reações adversas mediadas por mecanismos imunológicos e não relacionadas com as ações farmacológicas 
do fármaco. Podem ser classificadas quer com base na apresentação clínica, quer no mecanismo imunológico subjacente. Embora 
pouco comuns, as reações alérgicas a fármacos são imprevisíveis, podendo ser graves e potencialmente fatais. O objetivo da presente 
revisão da literatura foi disponibilizar aos clínicos de diversas áreas médicas uma ferramenta de trabalho para uma melhor abordagem 
dos seus doentes com suspeita de alergia a fármacos. Foi conduzida de forma não sistemática e procura descrever a complexidade 
das reações alérgicas a fármacos, desde a fisiopatologia à heterogeneidade da apresentação clínica. Foi dado especial destaque 
aos fármacos mais frequentemente envolvidos, à classificação das reações e aos fatores de risco. Apesar de todos os avanços nesta 
área desafiante e complexa da alergologia e imunologia clínica, a alergia a fármacos não está ainda completamente compreendida 
e estabelecida. A farmacogenética trouxe um contributo excecional, embora apenas para um número muito limitado de fármacos 
esteja definida uma associação farmacogenética. São necessários estudos adicionais que permitam obter respostas mais diretas na 
abordagem de cada caso individual de alergia a fármacos.    
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ABSTRACT
Drug therapy is often a balance between the beneficial and harmful effects of drugs. Drug allergic reactions are adverse reactions 
mediated by immunological mechanisms and usually not related to the pharmacological actions of the drug. They can be classified 
based either on the clinical presentation or the underlying immunological mechanism. Although uncommon, drug allergic reactions are 
unpredictable and can be very severe, even life threatening. The aim of this review was to provide clinicians from different medical 
specialties with a working tool to improve management of their patients with suspected drug allergy. It was conducted as a non-
systematic review, and attempts to describe the complexity of drug allergy. The information included ranges from pathophysiology to the 
heterogeneous clinical presentation, with a special focus on the drugs most frequently involved, as well as a classification of reactions 
and risk factors. Despite all advances in this challenging and complex field of allergy and clinical immunology, drug allergy is not yet fully 
established and understood. An exceptional contribution was brought by pharmacogenomics, even though a specific pharmacogenetic 
association has only been defined for a very limited number of drugs. Further studies are needed to obtain clearer answers when 
managing each individual case of drug allergy.
Keywords: Drug Hypersensitivity/etiology; Drug Hypersensitivity/immunology; Pharmacogenetics; Drug-Related Side Effects and 
Adverse Reactions
INTRODUCTION
 Drug therapy is often a balance between the beneficial 
and harmful effects of drugs. Despite the intensive research 
in the field, adverse drug reactions (ADRs) remain a major 
problem. An ADR has been defined by the World Health Or-
ganization as any noxious, unintended and undesired effect 
of a drug occurring at doses normally used for prevention, 
diagnosis or treatment.1 It has been estimated that ADRs 
account for 3% to 6% of all hospital admissions and oc-
cur in 10% to 15% of hospitalized patients, contributing to 
morbidity and mortality.2,3 A widely used classification sys-
tem divides ADRs in type A (predictable, common, related 
to the pharmacological properties of the drug), and type B 
(unpredictable, uncommon, unrelated to the pharmacolog-
ical actions of the drug). The first type comprises approxi-
mately 80% of all ADRs and includes drug-induced toxicity, 
side effects and drug interactions.4-7 Drug allergic reactions 
(DARs) are those mediated by immunological mechanisms 
and belong to type B. In practice, based on the clinical pre-
sentation alone, it is often difficult to differentiate between 
immune and non-immune mediated reactions. Therefore, 
the term drug hypersensitivity is applied when an immuno-
logical mechanism cannot be demonstrated in drug reac-
tions that clinically look like allergic. Drug hypersensitivity 
reactions (DHRs) comprise 15% of all ADR. DARs, although 
less common (estimated to represent a small percentage 
of all ADRs), can be very complex and potentially severe, 
even life-threatening.1,4 
 The study of DARs is challenging5 and is constantly 
updated as new drugs are developed and drug consump-
tion patterns are changed.6
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 The aim of this review of the current literature was to 
provide clinicians from different medical specialties with 
a working tool to improve management of their patients 
with suspected drug allergy (DA). It was conducted as a 
non-systematic review, and attempts to describe the com-
plexity of DA. The information included ranges from patho-
physiology to clinical presentation, with a special focus on 
the drugs most frequently involved, as well as classification 
of reactions and risk factors.
1 – Classification 
 A consensus classification is mandatory to guide and 
validate the diagnostic work-up. DARs can be classified 
based on the clinical presentation or the underlying immu-
nological mechanism (Table 1). 
 Clinically, DARs are classified depending on the time 
elapsed between drug administration and the onset of 
symptoms: immediate (usually occurring up to one hour; 
could be between 1 to 6 hours: accelerated reactions) and 
non-immediate (at any time, after one hour and up to sever-
al days of drug administration).4 
 Any of the four immunologic mechanisms proposed by 
Gell and Coombs may underlie DARs, being the IgE and 
T-cell-mediated the most common.4,9 Type I, also known as 
immediate reactions (IRs), are mediated by drug-specific 
IgE antibodies. Type II (cytotoxic) and Type III (immune 
complex) are mediated by drug-specific IgG or IgM anti-
bodies. Type IV are mediated primarily by T cells4-6,9-12 and 
have been recently classified in 4 subtypes, according to 
cytokine patterns and the preferential activation of different 
immunocytes.9  
2 – Clinical Presentation 
 2.1 – Immediate reactions (IRs): IRs present as isolat-
ed symptoms (urticaria, angioedema, conjunctivitis, rhinitis, 
bronchospasm) or as a severe reaction such as anaphy-
laxis. Urticaria/angioedema and anaphylaxis are the most 
common. The IgE-mediated allergy to β-Lactam (βL) antibi-
otics is the paradigmatic example.4,13,14 
 2.2 – Non-immediate reactions (NIRs): The skin is the 
most frequently involved organ, with a wide range of clini- 
cal presentations. Maculopapular exanthema (MPE) and 
delayed urticaria are the most common.4,6,10,13 Fixed drug 
eruption (FDE), acute generalized exanthematic pustulosis 
(AGEP), erythema multiforme (EM) and eczema are other 
presentations.12
 Both skin and other organs can be involved, as in drug 
rash with eosinophilia and systemic symptoms (DRESS)/
drug-induced hypersensitivity syndrome (DiHS), vasculitis 
and Stevens-Johnson syndrome (SJS)/ toxic epidermal 
necrolysis (TEN).4,6,10,13. 
 Mild eruptions usually occur one to few days after the 
drug treatment is started, while most severe reactions often 
 Table 1 - Classification of drug allergies (adapted from 4)
Type Type of immune response Pathophysiology
Timing of 
reaction Clinical symptoms
Typical chronology 
of the reaction
I IgE Mast cell and basophil 
degranulation
Immediate
Anaphylaxis 
Urticaria/Angioedema 
Bronchospasm 
Rhinitis
Immediate, usually up to one hour, 
but could occur between 1h to 6h 
after the last drug intake
II IgG and complement IgG and complement-
dependent cytotoxicity
Non-immediate
Cytopenia
5 – 15 days after the start of 
the eliciting drug
III IgM or IgG and 
complement or FcR
Deposition of 
immune complexes
Serum sickness 
Urticaria 
Vasculitis
7 – 8 days after the start of the 
eliciting drug for serum sickness/
urticaria; 
7 – 21 days for vasculitis
IV a Th1 (IFN-gamma) Monocytic inflammation Eczema 1 – 21 days after the start of 
the eliciting drug
IV b Th2 (IL-4 and IL-5) Eosinophilic 
inflammation
MPE 
DRESS/ DiHS
1 to several days after the start of 
the eliciting drug for MPE; 
2 – 6 weeks for DRESS/DiHS
IV c
Cytotoxic T cells 
(perforin, granzyme B, 
FasL, granulysin)
Keratinocytic death 
mediated by 
CD4 or CD8
MPE 
FDE 
SJS/TEN
1 – 2 days after the start of the 
eliciting drug for FDE; 
4 – 28 days for SJS/TEN
IV d T cells (IL-8/CXCL8) Neutrophilic 
Inflammation
AGEP
1 –2 days after the start of the 
elicitting drug, but can be longer
IgE: Immunoglobulin E; IgM: Immunoglobulin M;  IgG: Immunoglobulin G;  Th1: T helper1; Th2: T helper 2; IFN gamma: Interferon gamma; IL4: Interleukin 4; IL5: Interleukin 5; 
IL8: Interleukin 8; CXCL8: Chemokine motif ligand 8; MPE: Maculopapular exanthema; DRESS: Drug rash with eosinophilia and systemic symptoms; DiHS: Drug-induced hypersensitivity 
syndrome; FDE: Fixed drug eruption; SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; AGEP: Acute generalized exanthematic pustulosis.
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begin later on (SJS/TEN: 4 - 21 days; DRESS/DiHS: 2 - 6 
weeks).4 
 DRESS is an unusual DAR characterized by the pres-
ence of morbilliform rash, atypical lymphocytosis, eosino-
philia, fever and other organ involvement, usually liver.12,15 A 
minimum criterion of rash, fever, hepatitis and lymphocyto-
sis has been proposed for DiHS.16
 SJS and TEN, the most severe type of reactions affect-
ing the skin, are characterized by extensive epidermal de-
tachment and mucous membrane erosion, including oral, 
conjunctival and anal.10,12 Although uncommon (estimated 
prevalence: 5 - 6 cases and 1 - 2 cases per million patients 
for SJS and TEN, respectively),17 the morbidity and mortali-
ty is high (5% - 10% mortality for SJS16,17 and 30% - 50% for 
TEN).12,16-18 Several authors support that SJS and TEN are 
a single disease with common causes and physiopathology, 
but different spectrums of severity according to the exten-
sion of epidermal detachment (< 10% : SJS; 10% – 30% : 
SJS – TEN overlapping; > 30% : TEN).10,12,16-18 Drugs cau-
sing SJS/TEN overlap with those causing DRESS/DiHS: 
aromatic amine anticonvulsants, sulfonamides antibiotics, 
nonsteroidal anti-inflammatory drug (NSAIDs) and antiret-
roviral agents. Allopurinol and lamotrigine were also associ-
ated with SJS/TEN.10,12,16,17  
 EM is characterized by the presence of target-shaped 
lesions and, although less severe, can be an early presen-
tation of SJS/TEN. Any of these reactions contraindicate the 
re-administration of the culprit drug.12
3 – Pathogenesis and Physiopathology 
 3.1 – Chemical basis: For a drug to become an antigen 
able to elicit an immune response, two main mechanisms 
have been proposed: 1. The drug, a chemically reactive 
small-molecule, must bind irreversibly to a protein, gene- 
rating antigens (hapten concept); 2. The drug, chemically 
inert, needs to be converted into reactive metabolites before 
binding irreversibly to proteins (pro-hapten concept).4-5,19-22 
 For T-cell mediated reactions, the role of a carrier-pro-
tein/hapten has not been fully defined as it has been for 
IgE-mediated reactions.4,19  
 An alternative hypothesis is that some drugs might also 
originate a direct reversible interaction with the T-cell recep-
tors or HLA-molecules, activating T cells by pharmacological 
interaction (p-i concept).9 According to this hypothesis, the 
drug eliciting an immunological response is not dependent 
on its structural features nor metabolism. Chemically inert 
drugs are able to directly activate T-cell receptors.4-5,11,20,21 
 Cross-reactivity between drugs is an immunological 
reaction that occurs on exposure to different drugs with a 
similar molecular structure. This can happen even without 
any previous exposure to the cross-reacting drug, allowing 
to predict, to some extent, the risk of reactivity to chemically 
related drugs.11 
 3.2 – Immunopathological mechanisms: It has been 
proposed that drug-protein conjugates might be processed 
and presented by antigen-presenting cells to naive T cells, 
after drug intake, inducing tolerance or effector responses.24 
In the last case, the immune system develops either im-
mediate T-helper2 (Th2)- type responses, mediated by spe-
cific IgE antibodies, or non-immediate Th1-type responses, 
mainly mediated by specific T cells.5,10 Alternatively, T cells 
could be directly stimulated by the drug.9 
 3.2.1 – Immediate reactions: IRs develop as a result 
of IgE production. At an initial sensitization phase, B-cells 
proliferate and differentiate into plasma cells, in the pres-
ence of specific Th2-cells. Drug-specific IgE are then pro-
duced and bind to the high-affinity FcRI receptors on the 
surface of mast cells and basophils. On subsequent drug 
exposure, the drug antigen cross-links IgE on the surface of 
mast cells, activating them and inducing the release of pre-
formed mediators (e.g., histamine, tryptase, TNF-α) and the 
production of new ones (e.g., leukotrienes, prostaglandins, 
cytokines). The sensitization phase is usually asymptomatic 
and may have occurred during an earlier drug treatment.4,5 
 3.2.2 - Non-immediate reactions: The majority are me-
diated by T lymphocytes.4 Most of the information available 
relates to the specific effector immune response mediated 
by T cells. Little is known about the initial steps mediated by 
the innate immune system, mainly by dendritic cells.10,23 It 
has been proposed that these cells can process the drug 
antigen as a first step to stimulate naive T cells.4 The an-
tigen is internalized and transported to the regional lymph 
nodes, where it is presented to naive T cells. Alternatively, 
it may stimulate directly pathogen-specific T cells, without 
priming by dendritic cells. Antigen-specific T cells migrate to 
target organs and on re-exposure to the drug, are activated 
to secrete cytokines. 
 Other immune cells are involved in NIRs, fitting into the 
four subtypes of Type IV reactions9: IVa). Th1 cells produce 
interferon-γ-activated macrophages, typically in eczema; 
IVb). Th2 cytokines induce the production of antibodies by 
B cells and the eosinophil responses, mainly in MPE and 
DRESS; IVc). CD4+ and CD8+ T cells produce cytotoxic 
mediators leading to keratinocyte apoptosis in MPE and 
massive apoptosis in SJS/TEN; IVd). neutrophil recruitment 
and T-cell-induced activation by the production of a chemo-
kine, CXCL8, mainly in AGEP.
 The histopathology findings in SJS/TEN show detach-
ment of a large portion of the epidermis.12 Previously, Fas-
FasL interaction and perforin-granzyme B were the path-
ways reported as basic effectors.12,16 More recently, granu- 
lysin was described as a key effector responsible for the 
death of keratinocytes.16,18,24 Granulysin concentrations in 
blister fluid seem to correlate with the severity of SJS/TEN24 
and high granulysin serum levels may be a useful early dia- 
gnostic biomarker.18  
 In a minority of NIRs other immune mechanisms may 
be involved. Type II reactions concern IgG-mediated cyto-
toxicity directed to membranes of erythrocytes, leukocytes 
and platelets. Drugs typically involved are methyldopa (he-
molytic anemia), aminopyrine (leukopenia), and heparin 
(thrombocytopenia). Such reactions may occur only as long 
as the drug is present in soluble form. Type III reactions 
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involve the formation of immune complexes (IC), a common 
event in a normal immune response, usually asymptoma- 
tic. On rare occasions, IC bind to endothelial cells and lead 
to IC deposition with complement activation in small blood 
vessels, resulting in serum sickness syndrome (SSS), 
drug-induced lupus erythematosus or vasculitis.5
 3.3 – Pharmacogenetics: The discovery of strong as-
sociations between certain severe reactions, mostly NIRs, 
and HLA-B alleles has allowed a great progress in DA.4,16-
18,20,21 The association of HLA alleles with SJS/TEN has been 
reported, for the first time, more than 25 years ago.25 Since 
then, specific HLA alleles have been found to be associa- 
ted with this disease.17 A strong association between car-
bamazepine (CBZ)-induced SJS/TEN and HLA-B*1502 has 
been described in a Chinese population, where this allele 
was present in all patients suffering from CBZ-induced SJS. 
Subsequently this association was also found in Indian and 
Thai, but not in Japanese nor in European patients.16,21 This 
association seems to be phenotype-specific (SJS/TEN)4 
and is stronger than any other described so far.17,21 
 In northern Europeans, the presence of HLA-A*3101 
has been associated with a wide spectrum of CBZ-induced 
reactions (MPE, DRESS/DiHS, SJS/TEN).26 
 Other important association include HLA-B*5801 and 
SJS/TEN or DRESS/DiHS with allopurinol, in Asian16 and 
European populations.16,27 
 Finally, the carriage of HLA-B*5701 has been strong-
ly associated with flucloxacillin-induced liver injury16,21 and 
with abacavir hypersensitivity syndrome, a severe multi-or-
ganic reaction.16,21,28,29 This association was higher among 
Caucasians, where the allele was present in 94.4% cases 
(positive predictive value ≥ 70%; negative predictive value: 
95% - 98%).29 International HIV treatment guidelines re- 
commend the HLA-B*5701 screening prior to the abacavir 
treatment.30 
 Recent pharmacogenomic studies evolving from a 
candidate-gene approach to the genome-wide associa-
tion study (GWAS) brought great advances in the disco- 
very of genes associated with inter-individual differences 
in drug response (mainly genes predisposing to ADRs but 
also genes responsible for drug efficacy). The HLA system 
has been a major focus for type B reactions, particularly 
the more severe immune reactions.16,17 A number of poly-
morphisms located on chromosome 6 have been found in 
association with SJS/TEN induced by allopurinol31 and aba-
cavir.32 In IRs, some polymorphisms in cytokine genes have 
been weakly associated with βL-induced anaphylaxis.33-35  
 This greater knowledge has made some DARs quite 
predictable.16,20,21
 
 3.4 – Risk factors: There are few identified factors in-
fluencing the risk of sensitization and the severity of DARs. 
These are the chemical structure of the molecule, the na-
ture of drug exposure (dose, route, frequency and duration), 
the presence of co-factors (e.g. stress, infections), genetic 
predisposition, immune status and female gender.1,5,20 In 
the balance between drug and individual factors (Fig. 1), 
a disturbed immunologic status associated with the deve- 
lopment of recurrent infections, decreases the threshold to 
induce a response. Moreover, the HLA genotype can dictate 
the way in which a drug can cause allergy.22
 Anaphylaxis has been associated with certain drugs 
(NSAIDs, radiocontrast media, antibiotics, opioids, peri- 
operative drugs) in patients with mast cell disorders. How-
ever, data are scarce and evidence for an association is 
limited. Nevertheless, mastocytosis should be ruled out in 
cases of severe anaphylaxis.36  
 3.4.1 – The role of viruses: Viral infections are the 
main cause of skin reactions that can mimic DARs if the 
drug, usually an antibiotic, is taken simultaneously. Viruses 
can also interact with drugs and immune system, leading 
to allergic reactions such as the mild ampicillin exanthema 
linked to the Epstein-Barr virus (EBV) infection or DRESS/
DiHS.4,10,20-22,37,38 DRESS/DiHS is the best studied DAR 
associated with viral infection and has been linked to the 
reactivation of human herpes virus (HHV)-6. EBV, cytomeg-
alovirus and other HHV, even days or weeks after the dis-
continuation of the drug.4,10,16,22,38,39 
 The interaction with the immune system can occur at 
several points: drug metabolism; drug presentation to T 
cells, by dendritic cells; and effector response (cytokine and 
chemokine production).10
4 – Allergic reactions to specific drugs 
 4.1 – Antibiotics 
 4.1.1 – β-Lactams: βLs are still the most frequent cause 
of DARs. Benzylpenicillin was the first βL implicated, but 
amoxicillin has progressively become the most common 
culprit. A wide range of manifestations can occur, reflecting 
different underlying immunological mechanisms. They can 
induce IRs, mediated by IgE (usually urticaria/angioedema 
and anaphylaxis) and also NIRs (mainly MPE). Severe 
NIRs (AGEP, SJS/TEN, DRESS) can also occur.6,13 
Figure 1 – Drug Allergy: a balance between drug factors and patient 
biology (adapted from 21)
p-i concept: Pharmacological interaction with immune receptors.
Nature of Drug
Exposure
Drug Allergy
Individual factors:
  - Genetics
  - Disease
  - Co-factors
Chemistry:
  - Hapten/pro-hapten
  - p-i concept
Immunology:
  - Innate/Adaptive
    Immune System
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 βLs clearly induce immunological reactions due to hap-
ten-carrier formation which occur through the nucleophilic 
opening of the βL ring and the generation of reactive in-
termediates.6,13,22 Recent studies have pointed out the rele-
vance of the three-dimensional shape of the βL, as well as 
its inherent chemical reactivity, in determining the selectivity 
of the covalent binding.20 The role of side chains that distin-
guish different penicillin compounds as relevant allergenic 
determinants is also widely accepted, particularly in IRs to 
aminopenicillins and cephalosporins. Thus, cephalosporins 
with a similar side-chain should be avoided in patients with 
IgE-mediated reactions to penicillin.13,40 Moreover, in cases 
of IRs to penicillin, skin testing with alternative drugs (cepha- 
losporins, carbapenems, aztreonam) is recommended prior 
to its administration. If negative, the drug should be given by 
increasing doses in an appropriate setting.13 
 In NIRs to aminopenicillins, both core structure and 
the whole molecule (core structure plus the amino-benzyl 
group of the side-chain) are recognized by T cells, although 
the latter plays a predominant role.13 Despite the fact that 
cross-reactivity between penicillins, cephalosporins and 
carbapenems for T-cell reactions is very rare, it also de-
mands investigation.13,41 
 4.1.2 – Sulfonamides: Sulfonamides are defined as 
drugs with a SO2-NH2 moiety. Sulfonamide antibiotics also 
contain an aromatic amine (N4 position) and a substitu- 
ted ring (N1 position).40 After βLs, sulfonamide antibiotics 
(namely sulfamethoxazole-SMX) are the most common 
cause of DARs.40,42 SMX usually cause cutaneous NIRs 
and rarely IgE-mediated reactions12,22,40 through the direct 
activation of T cells by covalent binding or acting as 
pro-hapten, respectively, as SMX is a chemically inert 
drug.21,22,43,44 MPE is the most common presentation, but 
SJS/TEN were also described.12,22,40,42  
 About 40-80% of HIV patients treated with trimethoprim 
(TMP)-SMX develop a generalized MPE, usually accompa-
nied by fever, while the incidence of skin rashes to TMP-
SMX in healthy subjects is only 3% to 5%. The increased 
risk in HIV patients is probably related to immunologic and 
metabolic factors and to the frequent exposure to TMP-
SMX.42  
 The N4 aromatic amine is critical for the development 
of NIRs to sulfonamide antibiotics and the N1 substituted 
ring appears to be important for IgE-mediated reactions.  As 
non-antibiotic sulfonamides lack these structural compo-
nents, cross-reactivity with sulfonamide antibiotics is not ex-
pected.12,40,42 Conversely, all sulfonamide antibiotics should 
be considered to be cross-reactive.11
 4.1.3 – Fluoroquinolones: This widely used class of 
broad-spectrum antibiotics can induce reactions mediated 
by IgE (hapten-carrier formation) and T cells (p-i mecha-
nism).6,45-47 that are estimated to occur in 2% to 3% of the 
treated patients.45 IgE-mediated reactions are more com-
mon and usually severe, with anaphylaxis as the most fre-
quent presentation. Urticaria/angioedema can also occur. 
NIRs are less frequent and include MPE, FDE, vasculitis, 
AGEP and SJS/TEN.6,45-47 Moxifloxacin induces more se-
vere reactions6 and is the main culprit, followed by cipro-
floxacin and levofloxacin.6,46 As cross-reactivity between 
these antibiotics is common avoidance of all quinolones is 
advisable.12,48
 4.2 – Nonsteroidal anti-inflammatory drugs: NSAIDs 
are responsible for 21% to 25% of reported ADRs, including 
immunological and non-immunological reactions. Depen- 
ding on the clinical presentation and the presumable under-
lying mechanism, hypersensitivity to NSAIDs is classified 
in 2 groups and 5 subgroups (Table 2).49 In the first group 
(≥ 75% of cases),6 the putative mechanism is the inhibi-
tion of ciclooxigenase-1, hence hypersensitivity to multiple 
NSAIDs is observed regardless of their chemical structure 
and/or anti-inflammatory potency.49 
 The second group involves the selective reactions, 
probably with an underlying immunological mechanism: a) 
IgE-mediated is the proposed mechanism in cases of ur-
ticaria, angioedema and anaphylaxis induced by a single 
NSAID or a group of chemically related drugs.49,50 Pyrazolo-
nes, paracetamol, ibuprofen, diclofenac and naproxen are 
the most common.49 The last three compounds have a he-
teroaryl acetic group, presumably carrying a higher risk of 
anaphylaxis (OR 19.7);51 b) NIRs, probably T-cell mediated, 
were also reported to be induced by a single NSAID or a 
group of chemically related drugs.49-51 Cutaneous reactions, 
particularly MPE are the most frequent reaction. NSAIDs 
are the main cause of FDE and can also induce SJS/TEN 
(particularly oxicams).49  
 Diagnostic and management guidelines for children 
and adolescents with NSAIDs hypersensitivity, including a 
modified classification, were recently published considering 
specific clinical and epidemiological features.52 
 4.3 – Neuromuscular blocking agents (NMBAs): Im-
mediate HRs during the perioperative period have been 
increasingly reported.53 Most are mediated by IgE and 
less frequently related to direct stimulation of histamine re-
lease.53-55 
 IgE mechanism causes perioperative anaphylaxis (es-
timated incidence of 1:10 000 to 1:20 000) and any drug 
administered in this period can potentially induce it.53 Dif-
ferent populations exhibit different patterns of sensitiza-
tion.7 NMBAs are the most common cause in Europe (50% 
- 70%), followed by antibiotics and latex. While latex is be-
coming a less common culprit, chlorhexidine is gaining im-
portance and sugammadex is an emerging cause.54 
 Suxamethonium is the most frequent reported culprit, 
with a recent increment of rocuronium, vecuronium and 
pancuronium.53,56,57 Sensitization to NMBAs seems to de-
mand the presence of a substituted ammonium ion. In many 
cases, the reaction may occur at the first exposure, since a 
prior sensitization to another compound with a substituted 
ammonium ion (e.g. pholcodine) may have occurred.5,54,55,57 
Investigation of cross-reactivity between NMBAs is manda-
tory in diagnostic work-up.58-62
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 A new mast cell receptor MRGPRX2 (human Mas-rela- 
ted G-protein-coupled receptor member X2) was discov-
ered and related with reactions to NMBAs not IgE-mediat-
ed,54-55 which could explain the cases of perioperative ana-
phylaxis with negative skin testing (mast cell direct activa-
tion through this receptor).54
 4.4 – Radiocontrast media: In the past the ionic 
high-osmolar RCM induced a high incidence of IRs due to 
the nonspecific release of vasoactive mediators.6 Despite 
the introduction of nonionic (NI) low-osmolar RCM, hyper-
sensitivity reactions (HSRs) are still a matter of concern. A 
recent European multicenter study suggests that at least 
50% of the HRs to NI-RCM are caused by an immunological 
mechanism. Cross-reactivity was frequent among NI-RCM 
with a very similar chemical structure.58 It is estimated that 
NI-RCM can cause IRs and NIRs in about 1% - 3% of ap-
plications.59 IRs are mainly anaphylaxis, whereas NIRs pre-
dominantly manifest as mild skin eruptions occurring hours 
to days after RCM administration.58-62
 4.5 – Biological modifiers: The biologic agents have 
been recently developed and are increasingly used. They 
comprise proteins such as cytokines and monoclonal anti-
bodies (mAbs)6,40 that differ from other drugs as they have 
high molecular-weight with a great immunogenic potential.40 
Three major groups of mAbs are in use: chimeric (-ximab), 
humanized (-zumab) and human antibodies (-mumab). 
They can induce reactions through different immuno-
logical mechanisms.63,64 Clinical phenotypes include IRs 
(type I; infusion-related reactions, cytokine release, mixed 
reactions), type III and type IV delayed reactions.64  
 IgE-mediated reactions to basiliximab, infliximab and 
rituximab have been reported.6,7,42 IgE antibodies to cetu-
ximab specifically for alpha-1,3-galactose have been found 
in the majority of anaphylactic reactions.7,65 Rare delayed 
anaphylaxis has been reported after exposures to omali-
zumab, trastuzumab, daclizumab, infliximab and basili- 
ximab.12
 Some patients present IgG antibodies to biologics that 
may block the effect of the drug or be involved in the devel-
opment of HSRs.64 
 NIRS are rare but have been described, after rituximab 
(vasculitis, SSS)7 and infliximab (SSS, SJS, DiHS).40 
 Desensitization allows a safe reintroduction of first-line 
biologic agent.64,66 
 4.6 – Antineoplastic agents: HSRs to antineoplastic 
agents are an increasing problem.67,68 Any cytostatic can 
potentially expose the patient to the risk of an immune 
reaction. They can elicit either immediate (urticaria, bron-
chospasm, dyspnea, thoracic/abdominal pain, fever, ana-
phylaxis) or NIRs (macular/MPE, vasculitis). The severity 
of reactions ranges from mild symptoms to life-threatening 
anaphylaxis.67 
 HSRs are more common with platinum compounds (cis-
platin, carboplatin, oxaliplatin), epipodophyllotoxins (teni-
poside, etoposide), asparaginase, taxanes (paclitaxel) and 
procarbazine. Doxorubicin and 6-mercaptopurine are rare 
culprits. HSR to carboplatin and oxaliplatin are particular-
ly frequent (incidence: 12% - 17%), with more than 50% 
of the reactive patients developing moderate to severe 
Table 2 - Classification of Hypersensitivity Reactions Induced by NSAIDs (adapted from 55)
Type of reaction Clinical manifestations
Timing of 
reaction
Underlying 
disease
Cross-
reactivity
Presumable 
mechanism
NSAID-exacerbated 
respiratory disease  
(NERD)
Bronchospasm 
Nasal symptoms
Acute (usually 
immediate to 
several hours 
after exposure)
Asthma 
rhinosinusitis
Cross-
reactive
Non-allergic
COX-1 inhibition
NSAID-exacerbated 
cutaneous disease 
(NECD)
Urticaria and/or 
angioedema
Chronic urticaria
NSAID-induced urticaria/
angioedema 
(NIUA)
Unknown 
(probably COX-1 
inhibition)
Single NSAID-induced 
urticaria/angioedema or 
anaphylaxis 
(SNIUAA)
 Urticaria and/
or angioedema/ 
anaphylaxis
No underlying 
chronic disease
Non Cross-
reactive
Allergic
IgE-mediated
Single NSAID-induced 
delayed reactions 
(SNIDR)
Various symptoms and 
organs involved (eg. 
MPE, FDE, SJS/TEN, 
nephritis)
Delayed onset 
(usually > 24h 
after exposure)
T  cell-mediated
NSAID: Nonsteroidal anti-inflammatory drug; MPE: Maculopapular exanthema; FDE: Fixed drug eruption; SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; 
COX- 1: Ciclooxigenase 1; IgE: Immunoglobulin E.
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symptoms.69 
 Most reactions occur during the treatment (platinum 
derivatives and taxanes), although some appear hours af-
ter. Reactions to taxanes usually manifest during the first 
few minutes of the first or second infusion, whereas acute 
reactions to platinum agents usually occur after several cy-
cles.65,68,70-72 
 Since these drugs are usually the first line therapy, pa-
tients can be desensitized71 when no equally effective al-
ternative drugs are available. The desensitization should 
follow the general considerations for these procedures pu-
blished in a consensus paper for IRs73 and NIRs.74
CONCLUSION
 This exhaustive review, although the limitation of being 
non-systematic, pointed out that despite all advances, drug 
allergy is not yet fully established and understood. An ex-
ceptional contribution was brought by pharmacogenomics, 
even though a specific association has only been defined 
for a very limited number of drugs. Further investigation is 
needed to obtain clearer answers when managing each in-
dividual case of DA. The development of new biomarkers 
and a ‘tailored-made’ medicine is probably the future. 
 As knowledge in this field moves forward, new updates 
will be required.
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